Accéder au contenu
Merck

Acute lipopolysaccharide priming boosts inflammasome activation independently of inflammasome sensor induction.

Immunobiology (2012-08-18)
Kate Schroder, Vitaliya Sagulenko, Alina Zamoshnikova, Ayanthi A Richards, Jasmyn A Cridland, Katharine M Irvine, Katryn J Stacey, Matthew J Sweet
RÉSUMÉ

Macrophage pre-treatment with bacterial lipopolysaccharide (LPS) boosts subsequent activation of the NLRP3 inflammasome, which controls caspase-1-dependent pro-inflammatory cytokine maturation. Previous work has attributed this phenomenon (known as LPS 'priming') to LPS-dependent induction of NLRP3 expression. Whilst this plays a role, here we demonstrate that rapid LPS priming of NLRP3 inflammasome activation can occur independently of NLRP3 induction, since the priming effect of LPS is still apparent at short pre-treatment times in which NLRP3 protein expression remains unchanged. Furthermore, rapid LPS priming is still evident in Nlrp3(-/-) primary macrophages with NLRP3 expression reconstituted using a constitutive promoter. Similarly, we found that LPS potentiates AIM2 inflammasome activation to submaximal doses of cytosolic DNA without concomitant upregulation of AIM2 protein expression. Our data suggest that, in addition to augmenting NLRP3 inflammasome activity via NLRP3 induction, LPS boosts caspase-1 activation by the NLRP3 and AIM2 inflammasomes by an acute mechanism that is independent of inflammasome sensor induction.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Lipopolysaccharides from Salmonella enterica serotype minnesota, purified by gel-filtration chromatography